The humanization of pets and the increased and impulsive spending that goes along with that has been a trend for many years now.
A number of stocks have seen huge benefits including pharmaceutical related plays, veterinary supplies, food manufacturers, and more.
IDEXX Laboratories (NASDAQ:IDXX) produces diagnostic solutions for animal care and IT solutions for vets.
IDXX data by YCharts
Henry Schein (NASDAQ:HSIC) has human and pet focused dental and medical products.
Top Medical Stocks To Invest In Right Now: Insmed, Inc.(INSM)
- [By Lisa Levin]
Insmed Incorporated (NASDAQ: INSM) shares shot up 113 percent to $26.15 following the announcement of positive top-line results from its Phase 3 Convert study of ALIS in adult patients with treatment-refractory nontuberculous Mycobacterial (NTM) lung disease..
- [By Max Byerly]
TRADEMARK VIOLATION WARNING: “TIAA CREF Investment Management LLC Buys 13,438 Shares of Insmed, Inc. (INSM)” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at www.tickerreport.com/banking-finance/3353518/tiaa-cref-investment-management-llc-buys-13438-shares-of-insmed-inc-insm.html.
Top Medical Stocks To Invest In Right Now: Eli Lilly and Company(LLY)
- [By David Zeiler]
Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.
- [By Ben Levisohn]
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
- [By WWW.THESTREET.COM]
Cramer recalled recently investing in Eli Lilly (LLY) on hopes the company’s Alzheimer’s research would be worth billions. As time has worn on, Lilly’s obstacles to success seem to be mounting. Not knowing if or when Lilly might see success, Cramer said he sold the stock and moved on.
- [By ]
AbbVie (ABBV) : “I want to stay away from controversy. I like Eli Lilly (LLY) .”
Cramer and the AAP team note that seven of the companies in their portfolio are reporting this week, including Abbott Laboratories (ABT) , Nucor (NUE) and Honeywell (HON) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.
Top Medical Stocks To Invest In Right Now: PacWest Bancorp(PACW)
- [By Ben Levisohn]
The twenty stocks in Worth’s basket are: Ameriprise Financial (AMP) Bank of America, Banner (BANR), Citigroup, Citizens Financial Group (CFG), East West Bancorp (EWBC), First NBC Bank Holding (FNBC), HFF (HF), KeyCorp(KEY), Legacy Texas Financial Group (LTXB), Lincoln National (LNC), Morgan Stanley, Old National Bancorp (ONB), PacWest Bancorp (PACW), PNC Financial Services Group (PNC), Principal Financial Group (PFG), Stifel Financial (SF), SVB Financial Group (SIVB), TCF Financial (TCB), and Wells Fargo.
Top Medical Stocks To Invest In Right Now: AmerisourceBergen Corporation (Holding Co)(ABC)
- [By Ethan Ryder]
Alphabit (CURRENCY:ABC) traded down 14.2% against the US dollar during the 24-hour period ending at 19:00 PM Eastern on April 11th. Alphabit has a market cap of $0.00 and approximately $999.00 worth of Alphabit was traded on exchanges in the last 24 hours. One Alphabit token can now be purchased for about $33.91 or 0.00489408 BTC on cryptocurrency exchanges including C-CEX and Cryptopia. In the last week, Alphabit has traded up 2.4% against the US dollar.
- [By Ben Levisohn]
AmerisourceBergen (ABC) sprinted to the top of the S&P 500 after releasing Street-beating earnings this morning.
Shares of AmerisourceBergen jumped 8.8% to $$75.96 today, while the S&P 500 dropped fell 0.7% to 2,097.94.
Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:
This morningAmerisourceBergen reported adjusted EPS of $1.30, which was well ahead of Leerink/consensus of $1.22/$1.22. The quality of the beat appears decent, with some pressure in gross margin, completely offset by lower SG&A costs. Given the dramatic reduction in guidance provided byMcKesson (MP), investors had been very cautious heading into the quarter. We are pleased to see that F2017 EPS guidance of $5.63-$5.88 brackets Leerink/consensus estimates of $5.85/$5.82. Brand inflation is now expected to be in the +7-9% range from 10% previously, and F2017 is expected to be back-half loaded. Our first impression of the quarter is that the print and guide are good and there will likely be a relief rally in the shares.
AmerisourceBergen’s market capitalization rose to $18.1 billion from $16.6 billion yesterday.
Top Medical Stocks To Invest In Right Now: China Mobile (Hong Kong) Ltd.(CHL)
- [By Motif Investing]
The most heavily weighted names in the motif are China Mobile Ltd. (ADR) (NYSE: CHL), Aibaba Group Holding Ltd (NYSE: BABA), Baidu Inc (NASDAQ: BIDU), India's HDFC Bank (NYSE: HDB) and Russia's Mobile TeleSystems PJSC (NYSE: MBT).
- [By Lisa Levin]
In trading on Thursday, telecommunications services shares fell 0.12 percent. Meanwhile, top losers in the sector included China Mobile Ltd. (ADR) (NYSE: CHL), down 3 percent, and Partner Communications Company Ltd (ADR) (NASDAQ: PTNR), down 1.5 percent.
- [By David Goodboy]
Rumors are that Apple will use this opportunity to announce the long-awaited deal with China Mobile (NYSE: CHL), which is the world's largest cellphone carrier with more than 700 million active users. Clearly, there are impediments in the way, but the potential for a lower-priced iPhone for this market means strong possibilities remain. This deal would be a major upside catalyst for Apple shares.